Vascular changes may be linked with the occurrence of clinically adverse events related to CF-LVAD therapy, such as non-surgical bleeding, e.g., gastrointestinal bleeding related to arteriovenous malformations [21] or von Willebrand factor (vWF) deficiency [22], or other clinical complications such as cerebrovascular events [23,24], device thrombosis [25,26] or development of aortic insufficiency [27,28]. This evidence concerns the gene VWF and aortic valve insufficiency.